Term
| FONDAAPARINUX (ARIXTRA) AND RIVAROXABAN (XARELTO) ARE SELECTIVE FOR WHAT? |
|
Definition
| Xa WITH ALMOST NO EFFECT ON THROMBIN (NOT AS DIFFUSE OF AN ACTION; THROMBIN ACTIVATES ALOT OF THINGS, Xa STARTS COMMON PATHWAY) |
|
|
Term
| FONDAPARINUX AND RIVAROXABAN MAY BE REVERSIBLE WITH WHAT? IS THERE AN ANTIDOTE? |
|
Definition
| FACTOR CONCENTRATES, NO OFFICIAL ANTIDOTE |
|
|
Term
| WHAT IS XARELTO ON AVAILABLE IN? |
|
Definition
|
|
Term
| DIRECT THROMBIN INHIBITORS INLIKE HEPARIN DO OR DON'T ACT THROUGH ANTITHROMBIN? |
|
Definition
|
|
Term
| DIRECT THROMBIN INHIBITORS ARE USEFUL IN PTS WITH WHAT DISEASE? WHAT LAB SHOULD BE MONITORED? |
|
Definition
|
|
Term
| THE MEDICATIONS HIRUDIN, DESIRUDIN, LEPIRUDIN, AND BIVALIRUDIN ARE DERIVED FROM WHAT? HOW ARE THEY CLEARED? |
|
Definition
|
|
Term
| HIRUDIN, DESIRUDIN, LEPIRUDIN, AND BIVALIRUDIN SHOULD BE STOPPED HOW LONG BEFORE SURGERY? |
|
Definition
| SHOULD BE STOPPED 8 HRS BEFORE SURGERY, WITH THE EXCEPTION, OF BIVALIRUDIN, WHICH HAS A SHORT HALF LIFE AND CAN BE STOPPED 3 HRS PRIOR TO SURGERY. |
|
|
Term
| WHAT TYPE OF HALF LIFE DOES ARGATROBAN HAVE? |
|
Definition
|
|
Term
| WHEN IS ARGATROBAN PROLONGED? WHAT TYPE OF EXCRETION DOES IT HAVE? |
|
Definition
| NOT AFFECTED BY RENAL DISEASE, BUT PROLONGED WITH HEPATIC DISEASE. BILIARY EXCRETION. |
|
|
Term
| WHAT DOES ARGATROBAN PROMOTE THE RELEASE OF TO INCREASE PERFUSION? |
|
Definition
|
|
Term
| WHEN SHOULD ARGATROBAN BE DISCONTINUED BEFORE SURGERY? |
|
Definition
|
|
Term
| HOW IS DABIGATRAN (PRADAXA) ADMINISTERED? |
|
Definition
|
|
Term
| WHAT ARE 2 BENIFITS OF PRADAXA OVER COUMADIN? |
|
Definition
| NO MONITORING NECESSARY AND NO DIETARY RESTRICTIONS |
|
|
Term
| WHEN SHOULD DABIGATRAN (PRADAXA) BE DISCONTINUED PRIOR TO SURGERY? |
|
Definition
|
|
Term
| HOW DOES THROMBOLYTICS/FIBRINOLYTICS WORK? |
|
Definition
| PLASMINOGEN ACTIVATORS CONVERT PLASMINOGEN TO PLASMIN, WHICH BREAKS DOWN FIBRIN INTO FIBRIN SPLT PRODUCTS |
|
|
Term
| WHAT TYPE OF CLOTS IS THROMBOLYTICS/FIBRONOLYTICS MORE EFFECTIVE AT DISSOLVING? |
|
Definition
| NEW CLOTS VS OLDER, TIGHLY BOUND CLOTS |
|
|
Term
| WHAT ARE THE HALF LIVES OF ALL THROMBOLYTICS/FIBRINOLYTICS? |
|
Definition
|
|
Term
| WHAT ARE THE 2 MAIN SIDE EFFECTS WITH THROMBOLYTICS/FIBRINOLYTICS? |
|
Definition
| BLEEDING (ESPECIALLY INTRACRANIAL) AND HYPOTENSION (NOT NECESSARY BECAUSE OF BLEEDING) |
|
|
Term
| STREPTOKINASE IS A PROTEIN PRODUCED BY WHAT? |
|
Definition
| B-HEMOLYTIC STREP. ANTIGEN DEVELOPMENT AND ALLERGIC REACTION ARE MORE COMMON THAN WITH OTHER FIBRINOLYTICS. |
|
|
Term
| STREPTOKINASE MAY RESULT IN WHAT? |
|
Definition
|
|
Term
| WHAT IS A MAIN CONCERN FOR TISSUE PLASMINOGEN ACTIVATOR (TPA) ALTEPLASE |
|
Definition
| FIBRIN-SPECICIF, BUT SYSTEMIC BLEEDING IS STILL A CONCERN. MUCH MORE EXPENSIVE THEN STREPTOKINASE BUT MUCH MORE EFFECTIVE |
|
|
Term
| TENECTEPLASE (TNKASE) AND RETEPLASE (RETEVASE)ARE UNIQUE HOW? |
|
Definition
| THEY ARE GENETICALY ENGINEERED TPA TO INCREASE FIBRIN SPECIFICITY. |
|
|
Term
| REVERSAL OF FIBRONOLYTICS/THROMBOLYTICS IS THROUGH WHAT? |
|
Definition
|
|
Term
| WHEN SHOULD THROMBOLYTICS/FIBRINOLYTICS BE DISCONTINUED PRIOR TO SURGERY? |
|
Definition
|
|
